Glioblastoma is a formidable brain tumor known for its rapid growth and resistance to conventional treatments. Studies are constantly underway to identify new treatment strategies, and recently, a new biomarker named LCA168 has emerged as a potential focus for GBM treatment. LCA168 is a protein that is highly expressed in glioblastoma cells compar